2021
BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER
Kumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.Peer-Reviewed Original ResearchCSF tumor cellsLeptomeningeal diseaseBreast cancer patientsIntrathecal treatmentTumor cellsCase seriesOmmaya reservoirCancer patientsCerebrospinal fluidLarge prospective clinical trialsSmilow Cancer HospitalYale-New HavenMetastatic breast cancerProspective clinical trialsBarrow Neurological InstituteIntrathecal therapyTumor cell detectionFourth patientCancer HospitalTumor InstituteClinical managementClinical trialsBreast cancerTreatment responsePatients
2016
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement
Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016, 16: 842. PMID: 27809808, PMCID: PMC5096303, DOI: 10.1186/s12885-016-2890-0.Peer-Reviewed Original ResearchConceptsCase seriesAdvanced imagingTreatment planningCommon primary brain tumorNon-contrast enhancementPostcontrast MRI scansStandard care pathwayRecent clinical studiesPrimary brain tumorsContrast enhancementMagnetic resonance imaging (MRI) measurementsTumor Treating FieldsStandard treatment planningPrior therapyDisease activityNonmeasurable diseaseStandard therapySurvival benefitTumor burdenPoor prognosisTumor locationCare pathwayClinical evaluationClinical trialsPatient outcomes